Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Dynamics of Non-Canonical Amino Acid-Labeled Intra- and Extracellular Proteins in the Developing Mouse.

Saleh AM, Jacobson KR, Kinzer-Ursem TL, Calve S.

Cell Mol Bioeng. 2019 Aug 26;12(5):495-509. doi: 10.1007/s12195-019-00592-1. eCollection 2019 Oct.

PMID:
31719929
2.

Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis.

Bouton TC, de Vos M, Ragan EJ, White LF, Van Zyl L, Theron D, Horsburgh CR, Warren RM, Jacobson KR.

PLoS One. 2019 Oct 17;14(10):e0223308. doi: 10.1371/journal.pone.0223308. eCollection 2019.

3.

Non-Fatal Injuries and Injury Treatment in the West Coast Dungeness Crab Fishery.

Bovbjerg VE, Vaughan AM, Syron LN, Jacobson KR, Pillai S, Kincl LD.

J Agromedicine. 2019 Oct;24(4):316-323. doi: 10.1080/1059924X.2019.1638860. Epub 2019 Jul 23.

PMID:
31335297
4.

Discordant rifampicin susceptibility results are associated with Xpert® MTB/RIF probe B and probe binding delay.

Berhanu RH, Schnippel K, Kularatne R, Firnhaber C, Jacobson KR, Horsburgh CR, Lippincott CK.

Int J Tuberc Lung Dis. 2019 Mar 1;23(3):358-362. doi: 10.5588/ijtld.16.0837.

5.

Dungeness crab fishermen perceptions of injury causation and factors in staying safe.

Pillai S, Bovbjerg VE, Vaughan A, Jacobson KR, Syron LN, Kincl LD.

Int Marit Health. 2019;70(1):55-60. doi: 10.5603/IMH.2019.0008.

6.

Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.

Bulabula ANH, Nelson JA, Musafiri EM, Machekano R, Sam-Agudu NA, Diacon AH, Shah M, Creswell J, Theron G, Warren RM, Jacobson KR, Chirambiza JP, Kalumuna D, Bisimwa BC, Katoto PDMC, Kaswa MK, Birembano FM, Kitete L, Grobusch MP, Kashongwe ZM, Nachega JB.

Clin Infect Dis. 2019 Sep 27;69(8):1278-1287. doi: 10.1093/cid/ciy1105.

7.

Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol.

Myers B, Bouton TC, Ragan EJ, White LF, McIlleron H, Theron D, Parry CDH, Horsburgh CR, Warren RM, Jacobson KR.

BMC Infect Dis. 2018 Sep 29;18(1):488. doi: 10.1186/s12879-018-3396-y.

8.

Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis.

McIntosh AI, Jenkins HE, White LF, Barnard M, Thomson DR, Dolby T, Simpson J, Streicher EM, Kleinman MB, Ragan EJ, van Helden PD, Murray MB, Warren RM, Jacobson KR.

PLoS Med. 2018 Aug 21;15(8):e1002638. doi: 10.1371/journal.pmed.1002638. eCollection 2018 Aug.

9.

Brief Report: Pulmonary Tuberculosis Is Associated With Persistent Systemic Inflammation and Decreased HIV-1 Reservoir Markers in Coinfected Ugandans.

Olson A, Ragan EJ, Nakiyingi L, Lin N, Jacobson KR, Ellner JJ, Manabe YC, Sagar M.

J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):407-411. doi: 10.1097/QAI.0000000000001823.

10.

FDG-PET/CT activity leads to the diagnosis of unsuspected TB: a retrospective study.

Geadas C, Acuna-Villaorduna C, Mercier G, Kleinman MB, Horsburgh CR Jr, Ellner JJ, Jacobson KR.

BMC Res Notes. 2018 Jul 13;11(1):464. doi: 10.1186/s13104-018-3564-6.

11.

Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia?

Berhanu RH, Schnippel K, Kularatne R, Firnhaber C, Jacobson KR, Horsburgh CR, Lippincott CK.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):358-362. doi: 10.5588/ijtld.17.0837.

12.

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.

Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D.

Lancet Respir Med. 2018 Apr;6(4):265-275. doi: 10.1016/S2213-2600(18)30078-X. Erratum in: Lancet Respir Med. 2018 Apr 18;:.

PMID:
29595509
13.

Rethinking tuberculosis control by targeting previously treated individuals.

Brooks-Pollock E, Jacobson KR.

Lancet Glob Health. 2018 Apr;6(4):e361-e362. doi: 10.1016/S2214-109X(18)30068-8. Epub 2018 Feb 19. No abstract available.

14.

Acute HIV Discovered During Routine HIV Screening With HIV Antigen-Antibody Combination Tests in 9 US Emergency Departments.

White DAE, Giordano TP, Pasalar S, Jacobson KR, Glick NR, Sha BE, Mammen PE, Hunt BR, Todorovic T, Moreno-Walton L, Adomolga V, Feaster DJ, Branson BM.

Ann Emerg Med. 2018 Jul;72(1):29-40.e2. doi: 10.1016/j.annemergmed.2017.11.027. Epub 2018 Jan 6.

PMID:
29310870
15.

Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis.

Freiman JM, Jacobson KR, Muyindike WR, Horsburgh CR, Ellner JJ, Hahn JA, Linas BP.

J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):405-412. doi: 10.1097/QAI.0000000000001610.

16.
17.

HIV Prevention and Treatment: The Evolving Role of the Emergency Department.

Stanley K, Lora M, Merjavy S, Chang J, Arora S, Menchine M, Jacobson KR.

Ann Emerg Med. 2017 Oct;70(4):562-572.e3. doi: 10.1016/j.annemergmed.2017.01.018. Epub 2017 Mar 25. Review.

PMID:
28347557
18.

Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study.

Jacobson KR, Barnard M, Kleinman MB, Streicher EM, Ragan EJ, White LF, Shapira O, Dolby T, Simpson J, Scott L, Stevens W, van Helden PD, Van Rie A, Warren RM.

Clin Infect Dis. 2017 Jun 1;64(11):1502-1508. doi: 10.1093/cid/cix128. Erratum in: Clin Infect Dis. 2017 Oct 15;65(8):1431-1433.

19.

Tuberculosis.

Jacobson KR.

Ann Intern Med. 2017 Feb 7;166(3):ITC17-ITC32. doi: 10.7326/AITC201702070. Review.

PMID:
28166561
20.

High Feasibility of Empiric HIV Treatment for Patients With Suspected Acute HIV in an Emergency Department.

Jacobson KR, Arora S, Walsh KB, Lora M, Merjavy S, Livermore S, Menchine M.

J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):242-5. doi: 10.1097/QAI.0000000000001006.

PMID:
27028498
21.

Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis.

Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, Murray M.

J Clin Microbiol. 2016 Mar;54(3):727-33. doi: 10.1128/JCM.02775-15. Epub 2016 Jan 13.

22.

Scaling up multidrug-resistant tuberculosis care in China.

Jacobson KR, Sabin LL.

Lancet Glob Health. 2015 Apr;3(4):e183-4. doi: 10.1016/S2214-109X(15)70093-8. No abstract available.

23.

Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment.

Farhat MR, Mitnick CD, Franke MF, Kaur D, Sloutsky A, Murray M, Jacobson KR.

Int J Tuberc Lung Dis. 2015 Mar;19(3):339-41. doi: 10.5588/ijtld.14.0814.

24.

Alcohol, hospital discharge, and socioeconomic risk factors for default from multidrug resistant tuberculosis treatment in rural South Africa: a retrospective cohort study.

Kendall EA, Theron D, Franke MF, van Helden P, Victor TC, Murray MB, Warren RM, Jacobson KR.

PLoS One. 2013 Dec 13;8(12):e83480. doi: 10.1371/journal.pone.0083480. eCollection 2013.

25.

Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis.

Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, Murray MB.

J Antimicrob Chemother. 2014 Feb;69(2):331-42. doi: 10.1093/jac/dkt358. Epub 2013 Sep 20. Review.

26.

Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis.

Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC, Warren RM, Streicher EM, Calver A, Sloutsky A, Kaur D, Posey JE, Plikaytis B, Oggioni MR, Gardy JL, Johnston JC, Rodrigues M, Tang PK, Kato-Maeda M, Borowsky ML, Muddukrishna B, Kreiswirth BN, Kurepina N, Galagan J, Gagneux S, Birren B, Rubin EJ, Lander ES, Sabeti PC, Murray M.

Nat Genet. 2013 Oct;45(10):1183-9. doi: 10.1038/ng.2747. Epub 2013 Sep 1.

27.

Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa.

Jacobson KR, Theron D, Kendall EA, Franke MF, Barnard M, van Helden PD, Victor TC, Streicher EM, Murray MB, Warren RM.

Clin Infect Dis. 2013 Feb;56(4):503-8. doi: 10.1093/cid/cis920. Epub 2012 Oct 22.

28.

Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.

Mukinda FK, Theron D, van der Spuy GD, Jacobson KR, Roscher M, Streicher EM, Musekiwa A, Coetzee GJ, Victor TC, Marais BJ, Nachega JB, Warren RM, Schaaf HS.

Int J Tuberc Lung Dis. 2012 Feb;16(2):196-202. doi: 10.5588/ijtld.11.0116.

29.

Developing the HIV workforce: a case study of a training model for inexperienced HIV providers.

Jacobson KR, Wong A, Espinoza L, Ryu J, Chacko R, Fisher D, Gates JD.

J Health Care Poor Underserved. 2012 Nov;23(4):1502-11. doi: 10.1353/hpu.2012.0152.

PMID:
23698665
30.

Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa.

Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB.

Clin Infect Dis. 2011 Aug;53(4):369-72. doi: 10.1093/cid/cir406.

31.

Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis.

Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB.

Clin Infect Dis. 2010 Jul 1;51(1):6-14. doi: 10.1086/653115. Review.

32.

An analysis of published trials of interferon monotherapy in children with chronic hepatitis C.

Jacobson KR, Murray K, Zellos A, Schwarz KB.

J Pediatr Gastroenterol Nutr. 2002 Jan;34(1):52-8.

PMID:
11753165
33.

Open trial of flutamide for treatment of obsessive-compulsive disorder.

Altemus M, Greenberg BD, Keuler D, Jacobson KR, Murphy DL.

J Clin Psychiatry. 1999 Jul;60(7):442-5.

PMID:
10453797
34.

Normal CSF oxytocin and NPY levels in OCD.

Altemus M, Jacobson KR, Debellis M, Kling M, Pigott T, Murphy DL, Gold PW.

Biol Psychiatry. 1999 Apr 1;45(7):931-3.

PMID:
10202583

Supplemental Content

Loading ...
Support Center